Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Journal article
Jenkin D. et al, (2023), Lancet Infect Dis, 23, 956 - 964
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Journal article
Yin Z. et al, (2023), Cell Rep, 42
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria
Journal article
Li K. et al, (2023), Biophysical journal, 122, 144a - 145a
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Journal article
Li K. et al, (2023), Front Immunol, 14
Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies.
Journal article
Mugo RM. et al, (2023), PLoS One, 18
Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
Journal article
Morter R. et al, (2022), Frontiers in Immunology, 13
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article
Datoo MS. et al, (2022), Lancet Infect Dis, 22, 1728 - 1736
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Journal article
Madhavan M. et al, (2022), EBioMedicine, 85
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Journal article
Jenkin D. et al, (2022), Lancet Microbe, 3, e663 - e671
High-resolution African HLA resource uncoversHLA-DRB1expression effects underlying vaccine response
Preprint
Mentzer A. et al, (2022)
Vaccines against SARS-CoV-2
Chapter
Noé A. and Ewer K., (2022), Vaccinology and Methods in Vaccine Research, 201 - 222
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Preprint
Swanson PA. et al, (2021)
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Preprint
Flaxman A. et al, (2021)
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Barrett JR. et al, (2021), Nature medicine
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nature medicine
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Preprint
Emary KRW. et al, (2021)
IMPACT OF A DELAYED AND FRACTIONATED THIRD DOSE OF R21/MATRIX-M ADJUVANT IN UK ADULTS
Conference paper
Bellamy DG. et al, (2021), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 105, 372 - 372
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (vol 396, pg 1979, 2020)
Journal article
Ramasamy MN. et al, (2021), LANCET, 397, 1350 - 1350
THE R21/MATRIX-M (TM) MALARIA VACCINE CANDIDATE: A PHASE III TRIAL
Conference paper
Datoo MS. et al, (2021), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 105, 133 - 133